Cidara Therapeutics Inc (NASDAQ:CDTX) has been given an average recommendation of “Buy” by the ten analysts that are covering the stock. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $13.94.

Several research analysts recently weighed in on CDTX shares. Cantor Fitzgerald restated a “buy” rating and set a $9.00 target price on shares of Cidara Therapeutics in a research note on Thursday, March 16th. Zacks Investment Research upgraded Cidara Therapeutics from a “sell” rating to a “buy” rating and set a $8.00 target price on the stock in a research note on Thursday, February 23rd. HC Wainwright restated a “buy” rating and set a $18.00 target price (down from $25.00) on shares of Cidara Therapeutics in a research note on Wednesday, February 22nd. Needham & Company LLC dropped their target price on Cidara Therapeutics from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, February 21st. Finally, Jefferies Group LLC restated a “buy” rating and set a $15.00 target price on shares of Cidara Therapeutics in a research note on Friday, March 24th.

Cidara Therapeutics (NASDAQ:CDTX) traded down 2.29% on Tuesday, reaching $6.40. The company’s stock had a trading volume of 54,617 shares. The firm’s 50 day moving average price is $7.19 and its 200-day moving average price is $9.42. Cidara Therapeutics has a 1-year low of $6.30 and a 1-year high of $14.62. The company’s market capitalization is $107.53 million.

Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Wednesday, March 15th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.79) by $0.09. During the same period in the previous year, the firm posted ($0.72) earnings per share. Equities analysts forecast that Cidara Therapeutics will post ($3.44) earnings per share for the current year.

In other news, insider Kevin Forrest acquired 12,500 shares of the business’s stock in a transaction on Friday, March 31st. The stock was bought at an average cost of $7.75 per share, for a total transaction of $96,875.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jeffrey Stein acquired 12,900 shares of the business’s stock in a transaction on Friday, March 31st. The shares were purchased at an average price of $7.75 per share, with a total value of $99,975.00. The disclosure for this purchase can be found here. Corporate insiders own 22.20% of the company’s stock.

A number of large investors have recently bought and sold shares of the company. Interwest Venture Management Co. purchased a new stake in Cidara Therapeutics during the fourth quarter valued at approximately $14,111,000. Alyeska Investment Group L.P. purchased a new stake in Cidara Therapeutics during the fourth quarter valued at approximately $1,040,000. Perceptive Advisors LLC purchased a new stake in Cidara Therapeutics during the fourth quarter valued at approximately $8,043,000. Broadfin Capital LLC raised its stake in Cidara Therapeutics by 237.3% in the fourth quarter. Broadfin Capital LLC now owns 562,875 shares of the biotechnology company’s stock valued at $5,854,000 after buying an additional 396,000 shares during the period. Finally, Spark Investment Management LLC raised its stake in Cidara Therapeutics by 2.7% in the third quarter. Spark Investment Management LLC now owns 15,100 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 400 shares during the period. Institutional investors own 47.34% of the company’s stock.

WARNING: This article was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/04/18/cidara-therapeutics-inc-cdtx-given-consensus-recommendation-of-buy-by-brokerages.html.

About Cidara Therapeutics

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

5 Day Chart for NASDAQ:CDTX

Receive News & Ratings for Cidara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.